CLAIM AMENDMENTS

Claim 1: (cancelled).

Claim 2: (currently amended) A method of treating a disease responsive to modulation of the mGluR5a receptors comprising administering to a person in need of such treatment a therapeutically effective amount of a compound of the formula

$$R^3$$
 R^4
 R^5

I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl, unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl; R_7 , and R' are independently selected from the group consisting of, hydrogen or lower alkyl;

and B is selected from the group consisting of

wherein R⁶ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR and halogen;

R⁷— is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR', halogen, nitro, unsubstituted heteroaryl and heteroarylsubstituted by lower alkyl or cycloalkyl;

 \mathbb{R}^8 —is selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-OH, -(CH₂)_n—-C(O)OR" and aryl;

R⁹ is lower alkyl;

R¹⁰ — is selected from the group consistining of hydrogen, lower alkyl and halogen;

R¹¹—is selected from the group consisting of hydrogen and alkyl;

 R^{12} is $(CH_2)_n - N(R) - C(O)$ lower alkyl;

R¹³— is selected from the group consisting of hydrogen or lower alkyl;

 R^{14} , R^{15} , R^{16} and R^{17} are independently selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n halogen or lower alkoxy;

- R^{18} , R^{19} and R^{20} are independently selected from the group consisting of, hydrogen, lower alkyl, -(CH₂)_n-halogen and lower alkoxy;
- R²¹— is selected from the group consisting of hydrogen and lower alkyl;
- R²²— is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at least one substituent selected from hydroxy or halogen;
- R²³— is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl and nitro;

 R²⁴, R²⁵ and R²⁶ are independently selected from the group consisting of hydrogen and lower alkyl;
- n is 0, 1, 2, 3, 4, 5 or 6;
- X selected from the group consisting of-CH₂-, -O- and -S-; and
- Y is selected from the group consisting of -CH= and -N=; or a pharmaceutically acceptable salt thereof.

Claim 3: (cancelled).

Claim 4: (cancelled).

Claim 5: (currently amended) A method of treating pain comprising administering to a person in need of such treatment a therapeutically effective amount of a compound of the formula

$$R^3$$
 R^4
 R^5

I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, $-(CH_2)_n$ -halogen, lower alkoxy, $-(CH_2)_n$ -NRR', $-(CH_2)_n$ -N(R)-C(O)-lower alkyl, and aryl, unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl; R_5 and R' and R' are independently selected from the group consisting of hydrogen or lower

and B is selected from the group consisting of

alkyl;

wherein R⁶ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR and halogen;

R⁷— is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR', halogen, nitro or unsubstituted heteroaryl and heteroarylsubstituted by lower alkyl or eycloalkyl;

 R^8 — is selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n$ —OH, $-(CH_2)_n$ —-C(O)OR" and aryl;

R⁹——is lower alkyl;

R¹⁰ — is selected from the group consisting of hydrogen, lower alkyl and halogen;

R¹¹— is selected from the group consisting of hydrogen and alkyl;

 R^{12} — is $(CH_2)_n$ N(R) C(O) lower alkyl;

R¹³— is selected from the group consisting of hydrogen and lower alkyl;

R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n halogen and lower alkoxy;

 R^{18} , R^{19} and R^{20} are independently selected from the group consisting of hydrogen, lower alkyl, - $(CH_2)_n$ -halogen and lower alkoxy;

R²¹— is selected from the group consisting of hydrogen and lower alkyl;

R²²— is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at least one substituent selected from hydroxy or halogen;

R²³— is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl or nitro; R²⁴, R²⁵ and R²⁶ are independently selected from the group consisting of hydrogen and lower alkyl;

n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of-CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=; or a pharmaceutically acceptable salt thereof.

Claim 6: (currently amended) A method of treating anxiety or depression comprising administering to a person in need of such treatment a therapeutically effective amount of a compound of the formula

$$R^3$$
 R^4
 R^5

I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, - $(CH_2)_n$ -halogen, lower alkoxy, - $(CH_2)_n$ -NRR', - $(CH_2)_n$ -N(R)-C(O)-lower alkyl, and aryl, unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;

R₇ and R' and R" are independently selected from the group consisting of hydrogen or lower alkyl;

and B is selected from the group consisting of

$$R^{18}$$
 R^{19} R^{19} R^{21} R^{24} R^{24} R^{25} R^{25} R^{25} R^{26}

wherein R⁶ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n C(O)OR and halogen;

R²— is selected from the group consisting of hydrogen, lower alkyl, (CH₂), C(O)OR', halogen, nitro or unsubstituted heteroaryl and heteroarylsubstituted by lower alkyl or eyeloalkyl;

R⁸—— is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-OH, (CH₂)_n——C(O)OR" and aryl;

R⁹---is lower alkyl;

```
R<sup>10</sup> is selected from the group consisting of hydrogen, lower alkyl and halogen;
```

R¹¹— is selected from the group consisting of hydrogen and alkyl;

 R^{12} - is- $(CH_2)_n$ -N(R)-C(O)-lower alkyl;

R¹³— is selected from the group consisting of hydrogen and lower alkyl;

R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n halogen and lower alkoxy;

R¹⁸, R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, lower alkyl, - (CH₂)_n-halogen and lower alkoxy;

R²¹ — is selected from the group consisting of hydrogen and lower alkyl;

R²²—is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at least one substituent selected from hydroxy or halogen;

R²³— is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl or nitro;

R²⁴, R²⁵ and R²⁶ are independently selected from the group consisting of hydrogen and lower alkyl;

n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of-CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=;

or a pharmaceutically acceptable salt thereof.

Claim 7: (cancelled).

Claim 8: (cancelled).

Claim 9: (cancelled).

Claim 10: (cancelled).

Claim 11: (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula 1A

$$R^{3}$$
 R^{4}
 R^{5}

I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl;

R and R' are independently selected from hydrogen or lower alkyl; and B is

wherein

R¹⁸, R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen and lower alkoxy;

n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of-CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=;

or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier.

Claim 12: (cancelled).

Claim13: (currently amended) A compound of formula

$$R^3$$
 R^4
 R^5

I-A

wherein

R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl, unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;

R; and R' and R" are independently selected from the group consisting of hydrogen and or lower alkyl;

B is selected from the group consisting of

$$R^{18}$$
 R^{18} R^{19} R^{19} R^{20} R^{20}

wherein

R⁶——is selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-C(O)OR and halogen;

R⁷— is selected from the group consisting of hydrogen, lower alkyl, (CH₂), C(O)OR', halogen, nitro, unsubstituted heteroaryl and heteroaryl substituted by lower alkyl or cycloalkyl;

 R^8 — is selected from the group consisting of hydrogen, lower alkyl, $-(CH_2)_n$ —-C(O)OR" and aryl;

R⁹——is lower alkyl;

R¹⁰ — is selected from the group consisting of hydrogen, lower alkyl and halogen;

R¹¹— is selected from the group consisting of hydrogen and alkyl;

 R^{12} is $(CH_2)_n$ N(R) C(O) lower alkyl;

R¹³— is selected from the group consisting of hydrogen and lower alkyl;

```
R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> are independently selected from the group consisting of hydrogen, lower alkyl, (CH<sub>2</sub>)<sub>n</sub>-halogen or lower alkoxy;
```

 R^{18} , R^{19} and R^{20} are independently selected from the group consisting of hydrogen, lower alkyl, - $(CH_2)_n$ -halogen and lower alkoxy;

R²¹ — is selected from the group consisting of hydrogen and lower alkyl;

R²²— is selected from the group consisting of hydrogen, lower alkyl and lower alkyl substituted by at least one substitutent selected from hydroxy or halogen;

 R^{23} — is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl and nitro; R^{24} , R^{25} and R^{26} are independently selected from the group consisting of hydrogen or lower alkyl;

n is 0, 1, 2, 3, 4, 5 or 6;

X is selected from the group consisting of -CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=;

or a pharmaceutically acceptable salt thereof;

with the exception of

1-methyl-2-phenylethynyl-1H-imidazole,

1-methyl-2-(4-methoxy-phenylethynyl)-1H-imidazole,

1-methyl-5-phenylethynyl-1H-imidazole, and

1-methyl-4-phenylethynyl-1H-imidazole.

Claim 14: (cancelled).

Claim 15: (cancelled).

Claim 16: (cancelled).

Claim 17: (cancelled).

Claim 18: (cancelled).

Claim 19: (original) A compound selected from the group consisting of 3-phenylethynyl-4H-5-thia-2,6,9b-triaza-cyclopenta[a]naphthalene and 3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene.

Claim 20: (cancelled).

Claim 21: (cancelled).

Claim 22: (cancelled).

Claim 23: (cancelled).

Claim 24: (cancelled).

Claim 25: (cancelled).

Claim 26: (cancelled).

Claim 27: (cancelled).

Claim 28: (cancelled).

Claim 29: (cancelled).

Claim 30: (cancelled).

Claim 31: (cancelled).

Claim 32: (new) A process for the preparation of a compound of formula

$$R^3$$
 R^4
 R^5

I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl;

R and R' are independently selected from hydrogen or lower alkyl; and B is

wherein

R¹⁸, R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, lower alkyl, - (CH₂)_n-halogen and lower alkoxy;

n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of-CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=,

which process comprises reacting a compound of the formula

$$R^2$$
 R^3
 R^4
 R^5

with a compound of formula

wherein X signifies halogen or trifluoromethanesulfonyl.